Abstract
Due to defined molecular lesions and signaling pathway disruptions, brain tumors represent good candidates for targeted therapy. However, in brain tumors the blood-brain barrier may prevent the transfer of progress in the molecular neurosciences to the development of effective therapeutic strategies. In this article, the most advanced forms of targeted therapy for the treatment of brain tumors and their clinical results are presented.
Keywords
- Epidermal Growth Factor Receptor
- Clin Oncol
- Malignant Glioma
- Vascular Endothelial Growth Factor Receptor
- Primary Central Nervous System Lymphoma
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abbott NJ, Romero IA (1996) Transporting therapeutics across the blood-brain barrier. Mol Med Today 2:106–113
Benjamin R, Capparella J, Brown A (2003) Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 9:82–90
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012
Cloughesy TF, Kuhn J, Wen P, et al (2003) Two phase II trials of R115777 (Zarnestra®) in patients with recurrent glioblastoma multiforme: a comparison of patients on enzyme-inducing anti-epileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively: a North American Brain Tumor Consortium (NABTC) Report. Neuro-Oncol 5:349
Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16:1702–1708
Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901–903
Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309–1318
Fine HA, Figg WD, Jaeckle K, et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708–715
Fine HA, Wen PY, Maher EA, et al (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299–2304
Fine HA, Kim L, Royce C, et al (2005) Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23:1504a
Friedman HS, Quinn J, Rich J, et al (2005) Imatinib mesylate (Gleevec) plus hydroxyurea is an effective regimen in the treatment of recurrent malignant glioma. Phase 2 study results. J Clin Oncol 23:1515a
Galanis E, Buckner JC, Maurer MJ, et al (2005) N997B: phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): updated results and correlative laboratory analysis. J Clin Oncol 23:1505a
Grossman SA, Phuphanich S, Lesser G, Rozental J, Grochow LB, Fisher J, Piantadosi S (2001) New Approaches to Brain Tumor Therapy CNS Consortium. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 19:3260–3266
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA (2002) Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383–1388
Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93:14164–14169
Kesari S, Ramakrishna N, Sauvageot C, et al (2005) Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep 5:186–197
Kunwar S (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105–111
McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–60
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024
Newton HB (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2. Expert Rev Anticancer Ther 4:105–128
Raizer JJ, Abrey LE, Wen P, et al (2004) A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc Am Soc Clin Oncol 22:1502a
Reardon D, Friedman H, Herndon J, et al (2004) A phase I/II trial of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 23:110a
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115–122
Reese TS, Karnovsky MJ (1967) Fine structural localisation of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207–217
Rich JN, Reardon DA, Peery T, et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142
Sampson JH, Akabani G, Archer GE, et al (2003) Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27–35
Schlagetter KE, Molnar P, Lapin GD, et al (1999) Microvessel organisation and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 58:312–328
Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-b2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129–139
Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol 7:369
Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41:44–48
van den Bent M, Brandes A, Frenay M, et al (2005) Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. J Clin Oncol 23:118s
Wen PY, Yung W, Lamborn K, et al (2004) Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08). Poster presented at the Society for Neuro-Oncology 9th Annual Meeting, Toronto, Canada, November 18–21
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 5:2–23
Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr (2003) The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukaemia. Blood 101:5010–5013
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 8:2572–2578
Yung WK, Prados MD, Yaya-Tur R, et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771
Yung WK, Friedman H, Jackson E, Provenzale J, Leeds N, Conrad C, Walker A, Henry A, Huang J, Lauren D, Dugan M (2002) A phase I trial of PTK787/ZK22584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Am Soc Clin Oncol 21:79a
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Korfel, A., Thiel, E. (2007). Targeted Therapy and Blood-Brain Barrier. In: Dietel, M. (eds) Targeted Therapies in Cancer. Recent Results in Cancer Research, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-46091-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-540-46091-6_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-46090-9
Online ISBN: 978-3-540-46091-6
eBook Packages: MedicineMedicine (R0)